Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)

Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Fasching P, Jackisch C, Nekljudova V, Von Minckwitz G, Loibl S (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Annals of Oncology Elsevier

Book Volume: 28

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

HELIOS Kliniken DE Germany (DE) Luisenkrankenhaus Düsseldorf DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) St.Markus Koptisch-Orthodoxe Kirche Frankfurt e.V. DE Germany (DE) GBG Forschungs GmbH (German Breast Group) DE Germany (DE) Sana Klinikum Offenbach DE Germany (DE) SRH Wald-Klinikum Gera DE Germany (DE)

How to cite

APA:

Untch, M., Schneeweiss, A., Salat, C., Rezai, M., Zahm, D.-M., Klare, P.,... Loibl, S. (2017). Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto).

MLA:

Untch, M., et al. "Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)." 2017.

BibTeX: Download